BluGlass demonstrates feasible reliability of laser diodes
25 Nov 2022 - BluGlass Limited (ASX:BLG) President Jim Haden discusses achieving a key reliability milestone for the company's laser diodes.
25Nov
23Nov
The alternative to lithium
23 Nov 2022 - Altech Chemicals Limited (ASX:ATC) CFO Martin Stein discusses the recent joint venture with Fraunhofer IKTS and the CERENERGY solid state sodium alumina battery.
22Nov
Radiopharmaceutical Theranostics (ASX:RAD) to commence NSCLC trial in Australia
22 Nov 2022 - Radiopharmaceutical Theranostics Limited (ASX:RAD) Managing Director and CEO Riccardo Canevari discusses the progress of the company's brain, lung and prostate cancer therapies.
17Nov
Genetic Signatures (ASX:GSS) – detecting infectious diseases in high-throughput lab workflows
17 Nov 2022 - Genetic Signatures Limited (ASX:GSS) CEO and Director Dr John Melki discusses the company's technology, business model, 2022 highlights and outlook.
15Nov
Arovella Therapeutics (ASX:ALA) – tackling blood cancers and solid tumours
15 Nov 2022 - Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Dr Michael Baker provides an update on the company.
15Nov
OncoSil Medical (ASX:OSL) – targeted therapy for pancreatic cancer
15 Nov 2022 - OncoSil Medical Limited (ASX:OSL) Non-Executive Director Brian Leedman discusses joining the board of OncoSil and receiving CE mark approval for the company's therapy.
11Nov
K2fly (ASX:K2F) – providing ESG solutions for top 50 mining companies
11 Nov 2022 - K2fly Limited (ASX:K2F) CEO Nic Pollock discusses K2F's progress and milestones over the past year.
04Nov
Chimeric Therapeutics (ASX:CHM) enters research agreement to advance cell therapy portfolio
04 Nov 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses the company's new agreement with Case Western Reserve University.
03Nov
Antisense Therapeutics (ASX:ANP) appoints Chief Commercial Officer
03 Nov 2022 - Antisense Therapeutics Limited (ASX:ANP) Chair, Dr Charmaine Gittleson, and new Chief Commercial Officer, Dr Anthony Filippis, discuss Antisense's progress, attracting new talent to the company, and what drew Dr Filippis to the role.
02Nov
Novonix (ASX:NVX) receives US$150m grant for EV battery production
02 Nov 2022 - Novonix Limited (ASX:NVX) CEO Dr Chris Burns discusses news following the company's AGM, including the appointment of new directors and the expansion of the company's development capabilities.